Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon Neuroscience has completed dosing of the second cohort in the Phase 1 clinical study of DMT.
Moreau tells Proactive the study is to identify the safety and tolerability of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours which has never been studied clinically.
Proactive Investors
+1 604-688-8158
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.12 |
Daily Change: | -0.0031 -2.60 |
Daily Volume: | 4,772 |
Market Cap: | US$2.540M |
April 01, 2024 January 11, 2024 November 30, 2023 |
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORELithiumBank Resources is creating an opportunity to participate in the future of clean-tech energy. The company's strategy is to acquire claims in known lithium high grade hot spots with existing wells and infrastructure...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS